Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

NCT02470091 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT02470091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02470091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2015
Completion date
December 31, 2023
Enrollment
56 (actual)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic osteosarcoma, recurrent osteosarcoma, refractory osteosarcoma, stage iv osteosarcoma ajcc v7, stage iva osteosarcoma ajcc v7, stage ivb osteosarcoma ajcc v7